MedPath

Vortioxetine

Generic Name
Vortioxetine
Brand Names
Brintellix, Trintellix
Drug Type
Small Molecule
Chemical Formula
C18H22N2S
CAS Number
508233-74-7
Unique Ingredient Identifier
3O2K1S3WQV
Background

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Indication

用于治疗重度抑郁症成人患者。

Associated Conditions
Major Depressive Disorder (MDD)

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
First Posted Date
2017-04-11
Last Posted Date
2021-06-24
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
94
Registration Number
NCT03108625
Locations
🇵🇱

Centrum Badan Klinicznych PI-House Sp. z o.o., Gdańsk, Poland

🇵🇱

Samodzielny Publiczny Zaklad Opieki Zdrowotnej (SPZOZ) - Centrum Neuropsychiatrii "NEUROMED", Wrocław, Poland

🇷🇸

Clinic of Neurology and Psychiatry for Children and Adolescents, Belgrade, Serbia

and more 28 locations

THINC-it Vortioxetine - Sensitivity to Change

Phase 2
Completed
Conditions
Cognitive Change
Major Depressive Disorder
Interventions
Other: THINC-it Tool
First Posted Date
2017-02-15
Last Posted Date
2022-01-20
Lead Sponsor
Brain and Cognition Discovery Foundation
Target Recruit Count
158
Registration Number
NCT03053362
Locations
🇨🇦

CRTCE/KJK Healthplex, Toronto, Ontario, Canada

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2016-11-23
Last Posted Date
2019-07-11
Lead Sponsor
Takeda
Target Recruit Count
123
Registration Number
NCT02972632
Locations
🇺🇸

University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States

🇺🇸

Novex Clinical Research, LLC, New Bedford, Massachusetts, United States

🇺🇸

University of South Florida, Tampa, Florida, United States

and more 22 locations

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine

Phase 4
Terminated
Conditions
Depressive Disorder
Major Depression
Depression
Depression, Unipolar
Interventions
First Posted Date
2016-11-21
Last Posted Date
2019-10-14
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
2
Registration Number
NCT02969876
Locations
🇺🇸

the Massachusetts General Hospital, Boston, Massachusetts, United States

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Phase 4
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2016-10-13
Last Posted Date
2018-09-14
Lead Sponsor
Takeda
Target Recruit Count
361
Registration Number
NCT02932904

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

Phase 2
Completed
Conditions
Depressive Disorder, Major
Interventions
First Posted Date
2016-09-29
Last Posted Date
2018-06-20
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
55
Registration Number
NCT02919501
Locations
🇫🇮

FI1041, Helsinki, Finland

🇪🇪

EE1019, Tallinn, Estonia

🇫🇮

FI1040, Helsinki, Finland

and more 4 locations

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Phase 3
Terminated
Conditions
Depressive Disorder, Major
Interventions
First Posted Date
2016-08-18
Last Posted Date
2022-12-28
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
662
Registration Number
NCT02871297
Locations
🇿🇦

Cape Trial Centre, Bellville, Cape Town, South Africa

🇬🇧

NHS Greater Glasgow and Clyde Glasgow Clinical Research Facility-Queen Elizabeth University Hospi..., Glasgow, United Kingdom

🇪🇸

Hospital General Universitario Gregorio Maranon, Madrid, Spain

and more 75 locations

Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)

Phase 3
Withdrawn
Conditions
Major Depression
TBI
Interventions
Drug: Placebo
First Posted Date
2016-07-27
Last Posted Date
2016-09-02
Lead Sponsor
Johns Hopkins University
Registration Number
NCT02845349

The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2016-04-25
Last Posted Date
2021-10-04
Lead Sponsor
Rush University Medical Center
Target Recruit Count
31
Registration Number
NCT02749721
Locations
🇺🇸

Rush University Medical Center, Skokie, Illinois, United States

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
First Posted Date
2016-03-16
Last Posted Date
2020-08-19
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
784
Registration Number
NCT02709746
Locations
🇺🇸

US1386, Wichita, Kansas, United States

🇨🇴

CO1004, Bogotá, Colombia

🇨🇴

CO1002, Pereira, Colombia

and more 121 locations
© Copyright 2025. All Rights Reserved by MedPath